US · Healthcare · Medical Devices
EPS came in at -0.26 against a street estimate of -0.12 — a miss of 116.7%.
Analysts rate 20/20 Biolabs, Inc. Common Stock a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.00.
| Fund | Stake |
|---|---|
| Cresset Asset Management, LLC | 1.96% |
| HRT FINANCIAL LLC | 0.73% |
| Vanguard Fiduciary Trust Co | 0.43% |
| Geode Capital Management, LLC | 0.40% |
| Atlantic Union Bankshares Corp | 0.29% |
| Vanguard Capital Management, LLC | 0.20% |
| Citadel Advisors Llc | 0.19% |
| Bank of America Corp | 0.11% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for 20/20 Biolabs, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.